These 2 Companies Have No Competition
Warren Buffett has long championed the idea of investing in companies with durable competitive advantages. He believes that a business with true "moat" can more easily defend its market share from competitors and generate strong returns for shareholders
But if investing a company with a strong moat is a great idea, wouldn't it be even better to buy one that has no direct competition at all? Let's take a closer look at two companies that are void of rivals right now: Novocure (NASDAQ: NVCR), and Acadia Pharmaceuticals (NASDAQ: ACAD).
Image source: Getty Images.
Source: Fool.com
Acadia Pharmaceuticals Stock
€17.22
-0.640%
The stock is one of the favorites of our community with 29 Buy predictions and 1 Sell predictions.
With a target price of 31 € there is a hugely positive potential of 80.02% for Acadia Pharmaceuticals compared to the current price of 17.22 €.
